← All trials
NCT04365582
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2020
- Primary completion
- Jul 28, 2020
- Completion date
- Jan 28, 2021
- First posted
- Apr 28, 2020
- Last posted
- Apr 28, 2020
- Enrollment
- 640
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Groupe Hospitalier Paris Saint JosephLead sponsor
- Groupe Hospitalier Paris Saint JosephOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.